Prostate cancer diagnosis & treatment market was valued at $21,428.0 million in 2025 and is projected to reach $51,381.4 million by 2035, growing at a CAGR of 9.2% during the forecast period (2026-2035). The increasing incidence of prostate cancer is a key driver underpinning demand for diagnosis and treatment services in the market. According to the American Cancer Society, in the US alone, indicate that over 313,780 new prostate cancer cases were expected in 2025, accounting for about 30% of all male cancer diagnoses, and approximately 35,770 deaths from the disease were projected in the same year.
Browse the full report description of “Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035” at https://www.omrglobal.com/industry-reports/prostate-cancer-diagnosis-treatment-market
This sustained high incidence highlights the need for robust screening strategies and contributes to ongoing utilization of prostate-specific antigen (PSA) testing and digital rectal exams as first-line diagnostic techniques. The elevated burden of newly diagnosed cases directly expands the patient base requiring hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy, reinforcing baseline assumptions in market estimation models.
Prostate Cancer Cases and Deaths by age, 2025
Age, years | Cases | Deaths |
<50 | 3300 | 90 |
50–59 | 51,900 | 1190 |
60–69 | 133,040 | 5890 |
70–79 | 96,590 | 11,140 |
?80 | 28,950 | 17,460 |
All ages | 313,780 | 35,770 |
Source: American Cancer Society
Innovation Leaders Transforming the Prostate Cancer Diagnosis & Treatment Market
The key players in the prostate cancer diagnosis & treatment market include Johnson & Johnson, Astellas Pharma, Pfizer, Novartis, AstraZeneca, among others. These companies are advancing the prostate cancer diagnosis and treatment market through improved biomarker testing, PSMA-based imaging, and next-generation targeted and immunotherapy solutions. Continued innovation in radioligand therapies and hormone pathway inhibitors is enhancing treatment precision and clinical outcomes. Expanding regulatory approvals and clinical research activity are further strengthening standards of care across diagnostic and therapeutic segments.
Market Coverage
Key questions addressed by the report.
Global Prostate Cancer Diagnosis & Treatment Market Report Segment
By Diagnostic Techniques
By Therapy
Global Prostate Cancer Diagnosis & Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/prostate-cancer-diagnosis-treatment-market